At the time of writing, Immunome Inc [IMNM] stock is trading at $13.90, down -4.34%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IMNM shares have gain 2.66% over the last week, with a monthly amount glided 7.09%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on November 08, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $30. Previously, Piper Sandler started tracking the stock with Overweight rating on May 31, 2024, and set its price target to $27. On April 30, 2024, JP Morgan initiated with a Overweight rating and assigned a price target of $24 on the stock. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $35 on April 15, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $30 as its price target on January 29, 2024. Wedbush started tracking with a Outperform rating for this stock on December 19, 2023, and assigned it a price target of $12. In a note dated October 29, 2021, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $35 on this stock.
For the past year, the stock price of Immunome Inc fluctuated between $6.93 and $30.96. Currently, Wall Street analysts expect the stock to reach $23 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $13.90 at the most recent close of the market. An investor can expect a potential return of 65.47% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
According to Immunome Inc [NASDAQ:IMNM], the company’s sales were 10.13M for trailing twelve months, which represents an -18.37% plunge. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -31.34%, Pretax Profit Margin comes in at -30.15%, and Net Profit Margin reading is -30.15%. To continue investigating profitability, this company’s Return on Assets is posted at -1.19, Equity is -1.4 and Total Capital is -1.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.35 points at the first support level, and at 12.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.43, and for the 2nd resistance point, it is at 14.97.
Ratios To Look Out For
It is important to note that Immunome Inc [NASDAQ:IMNM] has a current ratio of 6.17. Further, the Quick Ratio stands at 6.17, while the Cash Ratio is 3.94. Considering the valuation of this stock, the price to sales ratio is 85.65, the price to book ratio is 3.91.
Transactions by insiders
Recent insider trading involved SIEGALL CLAY B, President and CEO, that happened on Nov 21 ’24 when 66057.0 shares were purchased. President and CEO, SIEGALL CLAY B completed a deal on Nov 22 ’24 to buy 33943.0 shares. Meanwhile, Chief Medical Officer Lechleider Robert bought 15805.0 shares on Nov 21 ’24.
